3 Pharmaceutical Company, Software and Digital Services Company and Travel Distribution Platform Stocks With a Strong Future Roadmap: Lupin, Sonata Software and TBO Tek

Pharma, software and travel platform stocks give investors a way to track businesses that sit close to everyday demand in India. Lupin, Sonata Software and TBO Tek cover a pharmaceutical company, a software and digital services company and a travel distribution platform.

This list covers three pharma, software and travel platform stocks with complete current figures: Lupin, Sonata Software and TBO Tek. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma, Software and Travel Platform Stocks?

Pharma, software and travel platform stocks are listed companies that develop and sell medicines in many countries, provide software and digital transformation services, and run a business to business platform that distributes travel products. Their earnings depend on prescription demand, client technology budgets and travel bookings.

Pharma, Software and Travel Platform Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing pharma, software and travel platform stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma, Software and Travel Platform Stocks Have a Strong Roadmap in India?

Pharma, software and travel platform stocks have a strong roadmap in India because growing global demand for affordable medicines, wider digital adoption in enterprises and rising air and hotel bookings keep widening the market for these companies.

• Pharma. Global markets need affordable medicines.
• Software. Enterprises keep digitising operations.
• Travel platform. Agents book more flights and hotels online.

Why Lupin Features Among These Pharma, Software and Travel Platform Stocks

Among the pharma, software and travel platform stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%.

Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Why Sonata Software Features Among These Pharma, Software and Travel Platform Stocks

Among the medicine, digital engineering and booking shares on this list, Sonata Software, based in Bengaluru, is a technology services company with a focus on the Microsoft ecosystem and a platform-led approach it calls modernisation.

The company has a return on equity of 26.7%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 6,732 crore. The stock trades at a P/E of 14.5, below the industry P/E of 17.5.

Revenue rose from Rs 5,655 crore in FY22 to Rs 10,806 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 376 crore in FY22 to Rs 464 crore in FY26, which works out to a compound annual growth rate of 5.4%. In the June 2026 quarter, revenue grew 9.9% year on year to Rs 3,286 crore.

Roadmap: Its strategy centres on cloud, data and artificial intelligence projects for retail, travel and manufacturing clients. A strong partner relationship with Microsoft and a pipeline of large deals support its roadmap.

What to watch: Monitor deal wins and trends in the domestic business.

Why TBO Tek Features Among These Pharma, Software and Travel Platform Stocks

Among the three companies on this list, TBO Tek runs a global business-to-business travel platform that connects suppliers such as hotels, airlines and activity providers with travel agents and corporate buyers across more than 100 countries.

Revenue rose from Rs 512 crore in FY22 to Rs 2,729 crore in FY26, a compound annual growth rate of 51.9%. Net profit grew from Rs 33.7 crore in FY22 to Rs 244 crore in FY26, which works out to a compound annual growth rate of 64.1%.

The company has a return on equity of 15.8%, a debt to equity ratio of 0.49 and a market capitalisation of Rs 17,527 crore. The stock trades at a P/E of 66.2, below the industry P/E of 121.2.

Roadmap: The company benefits from the move of travel booking to digital platforms and from rising outbound and inbound travel demand. Its network of suppliers and buyers makes the platform more useful as more partners join.

What to watch: Monitor transaction volumes on the platform and the growth of its hotel and international markets.

Lupin vs Sonata Software vs TBO Tek on Key Financials

The table below sets the three pharma, software and travel platform stocks side by side on revenue, profit and margin, using reported figures.

Sonata Software posts the highest return on equity in this group at 26.7%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and TBO Tek shows the fastest revenue growth with a 51.9% compound annual rate. A useful habit with pharma, software and travel platform stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pharma, Software and Travel Platform Stocks

Every theme carries risks that deserve a check before any decision. For these pharma, software and travel platform stocks, the main points are: Long-term medicine, digital engineering and booking shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Travel cycles. Bookings and occupancy follow travel demand.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma, software and travel platform stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma, Software and Travel Platform Stocks

Pharma, software and travel platform stocks work best when investors track growth, valuation and return on equity side by side. Lupin, Sonata Software and TBO Tek each have a clear plan to grow. Based on the 5 November 2026 close, Lupin trades at Rs 1,988, Sonata Software at Rs 237.72 and TBO Tek at Rs 1,576.5. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these pharma, software and travel platform stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track pharma, software and travel platform stocks, set price alerts and get research-backed stock ideas.

What are pharma, software and travel platform stocks?

Ans. Pharma, software and travel platform stocks are listed companies that develop and sell medicines in many countries, provide software and digital transformation services, and run a business to business platform that distributes travel products. Their earnings depend on prescription demand, client technology budgets and travel bookings. This list looks at three of them, Lupin, Sonata Software and TBO Tek, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.

Which pharma, software and travel platform stocks are covered in this list?

Ans. This list covers Lupin, Sonata Software and TBO Tek. Based on the 5 November 2026 close, Lupin traded at Rs 1,988, Sonata Software at Rs 237.72 and TBO Tek at Rs 1,576.5. Their return on equity ranges from 15.8% to 26.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.0% to 51.9%.

Why do pharma, software and travel platform stocks have a strong future roadmap in India?

Ans. Pharma, software and travel platform stocks have a strong roadmap in India because growing global demand for affordable medicines, wider digital adoption in enterprises and rising air and hotel bookings keep widening the market for these companies. The main drivers are as follows. Pharma. Global markets need affordable medicines. Software. Enterprises keep digitising operations. Travel platform. Agents book more flights and hotels online. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

How has Sonata Software performed financially?

Ans. Revenue rose from Rs 5,655 crore in FY22 to Rs 10,806 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 376 crore in FY22 to Rs 464 crore in FY26, which works out to a compound annual growth rate of 5.4%. In the June 2026 quarter, revenue grew 9.9% year on year to Rs 3,286 crore. The company has a return on equity of 26.7%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 6,732 crore. The stock trades at a P/E of 14.5, below the industry P/E of 17.5. Looking ahead, its strategy centres on cloud, data and artificial intelligence projects for retail, travel and manufacturing clients. A strong partner relationship with Microsoft and a pipeline of large deals support its roadmap.

How has TBO Tek performed financially?

Ans. Revenue rose from Rs 512 crore in FY22 to Rs 2,729 crore in FY26, a compound annual growth rate of 51.9%. Net profit grew from Rs 33.7 crore in FY22 to Rs 244 crore in FY26, which works out to a compound annual growth rate of 64.1%. The company has a return on equity of 15.8%, a debt to equity ratio of 0.49 and a market capitalisation of Rs 17,527 crore. The stock trades at a P/E of 66.2, below the industry P/E of 121.2. Looking ahead, the company benefits from the move of travel booking to digital platforms and from rising outbound and inbound travel demand. Its network of suppliers and buyers makes the platform more useful as more partners join.

What risks should investors check before buying pharma, software and travel platform stocks?

Ans. Investors should check a few risks before buying pharma, software and travel platform stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Travel cycles. Bookings and occupancy follow travel demand. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma, software and travel platform stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.